SKAN Group AG (SKAN) AI Stock Analysis

• Market Cap: CHF1.12B
• Dividend Yield: 0.84%
• Average Volume (3M): 22.50K
• Price to Earnings (P/E): 68.9
• Beta (1Y): 0.89
• Revenue Growth: -3.45%
• EPS Growth: -49.82%
• Country: CH
• Employees: 1,377
• Sector: Services
• Sector Strength: N/A
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.40
• Shares Outstanding: 22,483,524
• 10 Day Avg. Volume: 19,367
• 30 Day Avg. Volume: 22,504
• PEG Ratio: 0.92
• Price to Book (P/B): 8.73
• Price to Sales (P/S): 4.74
• P/FCF Ratio: -241.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF77.50
• Price Target Upside: 61.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: CHF49.00 ▲(2.40% Upside)

SKAN Group AG's strong financial performance is overshadowed by bearish technical indicators and high valuation metrics. The stock's overvaluation and negative market momentum are significant concerns, despite its solid financial health.

SKAN Group AG Business Overview & Revenue Model

Company Description

SKAN Group AG (SKAN) is a leading provider of engineering and technology solutions for the pharmaceutical and biotechnology industries, specializing in aseptic processing and containment. The company operates primarily in the sectors of cleanroom technology, automation, and process validation, offering a range of core products and services that include modular cleanroom systems, containment solutions, and consulting services for regulatory compliance and process optimization.

How the Company Makes Money

SKAN generates revenue through multiple streams, primarily from the sale of its modular cleanroom systems and containment solutions, which are essential for maintaining sterile environments in pharmaceutical production. The company also earns income through consulting services that assist clients with regulatory compliance, process validation, and optimization. Additionally, SKAN engages in partnerships with key players in the pharmaceutical sector, enhancing its market reach and client base. The company may also benefit from ongoing maintenance contracts and training services, which provide recurring revenue opportunities. Overall, SKAN's focus on high-quality engineering solutions and customer service positions it well to capitalize on the growing demand in the pharmaceutical and biotechnology industries.

SKAN Group AG Financial Statement Overview

Summary

SKAN Group AG shows strong financial performance with robust revenue and profit growth. The income statement is impressive, and the balance sheet is stable, though cash flow management needs improvement due to high capital expenditures.

Income Statement

SKAN Group AG has demonstrated strong revenue growth, with Total Revenue increasing consistently over the years. The Gross Profit Margin and Net Profit Margin have remained robust, indicating effective cost management and profitability. The EBIT and EBITDA margins are healthy, showcasing operational efficiency. Overall, the company displays a solid income statement performance with positive growth trends.

Balance Sheet

The company's balance sheet is stable, supported by a reasonable Debt-to-Equity Ratio, indicative of prudent leverage levels. The Return on Equity is strong, reflecting good profitability relative to equity. The Equity Ratio shows a solid equity base compared to total assets, enhancing financial stability. However, some attention is needed on total liabilities, which have grown over time.

Cash Flow

SKAN Group AG's cash flow performance is mixed, with fluctuating free cash flow levels. The Operating Cash Flow to Net Income Ratio is favorable, showing effective cash generation from operations. However, recent negative Free Cash Flow suggests high capital expenditures impacting cash reserves. The company needs to manage investing activities to maintain liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	332.13M	361.30M	320.02M	276.95M	234.26M	191.69M
Gross Profit	240.89M	265.88M	234.08M	200.50M	170.11M	133.00M
EBITDA	36.38M	59.68M	50.14M	40.15M	32.38M	16.48M
Net Income	16.18M	38.80M	26.31M	18.99M	10.62M	4.53M
Balance Sheet
Total Assets	381.49M	384.49M	373.45M	388.35M	331.92M	259.54M
Cash, Cash Equivalents and Short-Term Investments	52.94M	61.71M	85.12M	135.98M	131.54M	63.82M
Total Debt	10.02M	10.61M	6.49M	16.88M	15.27M	7.45M
Total Liabilities	198.06M	181.92M	197.09M	222.76M	157.92M	176.98M
Stockholders Equity	177.16M	196.16M	169.23M	157.30M	159.75M	41.65M
Cash Flow
Free Cash Flow	18.38M	-7.09M	-26.60M	32.62M	-32.29M	8.07M
Operating Cash Flow	68.58M	46.70M	8.70M	61.48M	10.32M	22.63M
Investing Cash Flow	-52.28M	-69.06M	-17.35M	-76.42M	-11.02M	-15.95M
Financing Cash Flow	-10.54M	-9.35M	-15.80M	-4.85M	67.48M	-8.15M

SKAN Group AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 47.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SKAN, the sentiment is Negative. The current price of 47.85 is below the 20-day moving average (MA) of 52.07, below the 50-day MA of 55.02, and below the 200-day MA of 67.08, indicating a bearish trend. The MACD of -1.95 indicates Positive momentum. The RSI at 27.36 is Positive, neither overbought nor oversold. The STOCH value of 34.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SKAN.

SKAN Group AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SFSN	72 Outperform	CHF4.08B	17.29	―	1.98%	-0.71%	-6.12%
STMN	72 Outperform	CHF15.43B	39.28	―	0.98%	4.49%	45.08%
COTN	66 Neutral	CHF1.47B	37.73	―	0.79%	27.24%	122.39%
TECN	64 Neutral	CHF1.76B	27.76	4.57%	2.22%	-9.34%	-37.50%
YPSN	58 Neutral	CHF4.20B	48.04	13.49%	0.71%	36.54%	11.60%
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%
SKAN	55 Neutral	CHF1.12B	68.94	―	0.84%	-3.45%	-49.82%

SKAN Group AG Corporate Events

SKAN Group AG Adjusts 2025 Financial Expectations Amid Project Delays

SKAN Group AG announced that it will not meet its revenue and profit expectations for 2025 due to project delays, resulting in a decline in net revenue and a lower EBITDA margin for the year. Despite these setbacks, the company reports a positive order intake, particularly in oncology and biotechnology sectors, laying a strong foundation for a successful fiscal year 2026. The company’s medium- and long-term growth prospects remain positive, supported by structural market growth and a robust project pipeline.

The most recent analyst rating on (CH:SKAN) stock is a Hold with a CHF57.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.

SKAN Group Announces CEO Transition to Jonas Greutert

SKAN Group has announced a CEO transition, with Jonas Greutert set to take over from Thomas Huber on January 1, 2026. Under Huber’s leadership, SKAN became a world leader in isolator systems for aseptic production, achieving significant sales growth and international expansion. Greutert, with a strong background in pharmaceutical technology and industrial automation, is expected to continue this growth trajectory, focusing on business expansion, profitability, and innovation.

The most recent analyst rating on (CH:SKAN) stock is a Buy with a CHF80.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.

SKAN Group AG Reports Strong Order Intake Amid Project Delays

In the first half of 2025, SKAN Group AG experienced a significant increase in order intake by 20.2% to CHF 213 million and achieved a record order backlog of CHF 386.4 million. Despite this, net sales decreased due to project delays, particularly in vaccine lines, leading to a slightly positive EBITDA and a negative net result. The company is advancing strategic initiatives for integrated process systems and standardization, and the recent acquisition of Metronik enhances its offerings across the pharmaceutical value chain. SKAN remains confident in achieving its full-year guidance, supported by a strong order pipeline and pre-productions of standard isolators.

The most recent analyst rating on (CH:SKAN) stock is a Buy with a CHF92.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.